ISI Group Is Bullish On AMLN, HGSI, GENZ And DNDN

Mark Schoenebaum of ISI Group said on CNBC's Fast Money that he is looking at biotech stocks that have a specific catalyst.

He believes that Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is a stock to watch, and sees it over $20 by the end of the year. Amylin has a diabetes drug that should be approved in October. Mark Schoenebaum sees that as a catalyst for a price increase.

Human Genome Sciences (NASDAQ: HGSI) has a drug for lupus, which could be approved by the end of the year. Mark Schoenebaum expects HGSI to jump approximately 20%.

He thinks that AMLN and HGSI will perform well regardless how investors generally feel about biotech.

Genzyme Corporation (NASDAQ: GENZ) is a turnaround story. The company has manufacturing problems and is poorly managed, but some due diligence reports indicate that things are going to change. If this happens Genzyme Corporation (GENZ) should gain 10%-20%, thinks Mark Schoenebaum.

Mark Schoenebaum thinks that Dendreon Corporation (NASDAQ: DNDN) can sell its prostate cancer drug alone. He said that there are a lot of examples of companies that can grow by selling cancer drugs. They can't sell drugs to millions of customers because they would need a few thousand people to sell the drugs, but DNDN won't be selling its drug to millions, and it takes just a couple hundred salesmen to do this job. The price tag for Dendreon (DNDN) is scary, explained Mark Schoenebaum, but it is still in the range.